Session Synopsis: Precision medicine holds tremendous promise for improved patient outcomes, but its full potential can only be realized as part of a comprehensive move toward precision health. This session will consider how to achieve a model in which care is centered around the individual and curated to fit their precise needs.
Session Chair Profile
M.D., MS, Executive Vice President and Chief Medical Officer, Aetna
Harold L. Paz, M.D., M.S., is executive vice president and chief medical officer for Aetna. He leads clinical strategy and policy at the intersection of all of Aetna’s domestic and global businesses. Before joining Aetna in 2014, Dr. Paz served as chief executive officer of Penn State Hershey Medical Center and Health System, senior vice president for Health Affairs for Penn State University, dean of its College of Medicine and professor of medicine and public health sciences. Prior to his appointment to Penn State, he served as dean of the Robert Wood Johnson Medical School and chief executive officer of Robert Wood Johnson University Medical Group. He is professor adjunct of internal medicine at Yale University School of Medicine and remains clinically active in pulmonary medicine. He has authored more than 85 publications.
Ph.D., Vice President, Research Strategy, Leukemia and Lymphoma Society
Dr. Amy Burd first began working with The Leukemia & Lymphoma Society in 2009 as senior director of LLS’s Therapy Acceleration Program, a strategic initiative through which LLS partners directly with biotechnology companies to help accelerate the development of promising therapies. In this role, she managed due diligence process for identifying strategic partnerships. In her current role, Dr. Burd provides strategic planning and oversight for mission special initiatives. She also leads LLS’s Beat AML initiative, a significant multi-institution collaboration to change the paradigm of treatment and improve outcomes for patients with acute myeloid leukemia (AML). Dr. Burd also leads other special research initiatives and collaborations. Prior to joining LLS, Dr. Burd was oncology portfolio manager at Bayer Pharmaceuticals and consultant to small biotechnology companies. Dr. Burd earned her doctorate in pharmacology from University of Minnesota-Twin Cities and her Bachelor of Science degree from Ohio Northern University.
M.D., Ph.D., Executive Director of Precision Medicine & Precision Genomics, Intermountain Healthcare
Lincoln Nadauld, MD, PhD, is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare. Dr. Nadauld recently participated in the Precision Medicine Initiative Summit and roundtables at the White House with President Barack Obama. He also attended Vice President Joe Biden’s Cancer Moonshot Summit, where the Oncology Precision Network (OPeN), spearheaded by Dr. Nadauld, was mentioned among the Vice President’s remarks. OPeN is a consortium of healthcare partners working to advance data-sharing in precision medicine, including genomic information and outcomes. Dr. Nadauld completed his undergraduate education at Brigham Young University, and went on to complete combined MD/PhD and clinical training at the University of Utah. He completed clinical training in Medical Oncology at Stanford University School of Medicine, where he completed a postdoctoral fellowship in solid tumor genomics.
M.D., SM, Harold H. Hines, Jr. Professor of Medicine, Yale School of Medicine
Harlan Krumholz is a cardiologist, health care improvement expert, and health care scientist at Yale. He is Director of the Yale-New Haven Hospital Center for Outcomes Research and Evaluation and Co-Director of the Robert Wood Johnson Foundation Clinical Scholars Program at Yale. He has led initiatives to improve the quality and outcomes of clinical decisions and health care delivery, enable transparency in practice and research, and avoid wasteful practices. He began the Yale Open Data Access Project to promote data sharing and open science. He founded Hugo, a mobile app to empower people with their health-related data, promoting the possibility of a consumer-mediated information platform. He is a founding member of the Board of Governors of the Patient-Centered Outcomes Research Institute. Dr. Krumholz received a BS from Yale, an MD from Harvard Medical School, and a Masters in Health Policy and Management from the Harvard University School of Public Health.